Carl K Wong

US Patent:

20210244621, Aug 12, 2021

Filed:

Apr 1, 2021

Appl. No.:

17/220732

Inventors:

- Pinole CA, US
Carl Wong - Cerritos CA, US
Albert Alaan - Redondo Beach CA, US
Taiki Nishihara - Berkeley CA, US
Harsh Raj Chauhan - Berkeley CA, US

Assignee:

Agape Assets, LLC - Pinole CA

International Classification:

A61J 7/04
A61F 9/00

Abstract:

A medication adherence device may include a unibody and a station. The unibody may include: a unibody housing configured to be removably coupled to a medicine container; an inertial measurement unit configured to record motion data describing the movement of the unibody, and therefore describing the movement of a medicine container that the unibody is coupled to; and a unibody data interface in communication with the inertial measurement unit. The station may include: a station data interface configured to receive motion data from the unibody data interface; and a station processing unit in communication with the station data interface, the station processing unit configured to generate medication access information using the motion data. Preferably, data and power may be communicated between the unibody and station when the unibody is positioned proximate to the station, such as by being positioned in a station cavity.

US Patent:

20200155415, May 21, 2020

Filed:

Jan 23, 2020

Appl. No.:

16/750452

Inventors:

- Pinole CA, US
Carl Wong - Cerritos CA, US
Albert Alaan - Redondo Beach CA, US
Harsh Raj Chauhan - Berkeley CA, US
Taiki Nishihara - Berkeley CA, US
Ryan Zolyomi - Santa Clara CA, US
Kian Talaei - Berkeley CA, US
Tianyi Xing - Berkeley CA, US
Fang-Jhen Su - Taichung City, TW

Assignee:

Agape Assets, LLC - Pinole CA

International Classification:

A61J 7/04
A61F 9/00

Abstract:

A system for promoting medication adherence is provided. The system may receive medical information and medication access information via a medication adherence device, the medication adherence device having a housing configured to be removably coupled to a medicine container. The information may be used to form one or more blind spots which representative of symptoms of glaucoma and which may be produced on the display screen of a patient's client device. The system may use Gamblification and/or Gamification in which a blind spot obscures portions of a game of chance program and/or novelty game type program, respectively, from being observed on the display screen. As medical information and medication compliance information is received, the number, size, opacity, and/or shape of the blind spots produced on the display screen of a patient's client device may change to provide actual perception of visual loss which spurs patients to compliance.